Company
Headquarters: Dalian, China
Employees: 222
CEO: Mr. Tiewei Song
$24.5 Million
USD as of Jan. 1, 2024
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
BIMI International Medical Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. It offers prescription and over-the-counter drugs, nutritional supplements, health foods, and sundry products, as well as traditional Chinese medicines, personal and family care products, and miscellaneous items under the Lijiantang Pharmacy brand name. The company also provides IT research and development services. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BOQI International Medical Inc. and changed its name to BIMI International Medical Inc. in June 2021. BIMI International Medical Inc. was incorporated in 2000 and is based in Dalian, the People's Republic of China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
BOQI International Medical Inc. has the following listings and related stock indices.
Stock: NASDAQ: BIMI wb_incandescent